Fri Nov 15 05:49:56 UTC 2024: ## PRECISE-DAPT Score Shows Promise in Predicting GI Bleeding After PCI in Hispanic Patients on Dual Antiplatelet Therapy

**EL PASO, TX** – A new study presented at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting suggests that the PRECISE-DAPT score could be a valuable tool for predicting gastrointestinal (GI) bleeding risk in patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).

The research, conducted at the Texas Tech University Health Sciences Center El Paso, focused on a predominantly Hispanic population in Texas, where 2.5% of post-PCI patients on DAPT experienced GI bleeding within the first year. The study found that the PRECISE-DAPT score, which incorporates factors like age, creatinine clearance, hemoglobin, white blood cell count, and history of spontaneous bleeding, demonstrated moderate accuracy in predicting GI bleeding risk in both high-risk and moderate-risk patients.

“This score could be a crucial tool for clinicians in identifying those patients who might benefit from more vigilant monitoring and potentially even adjustments to their DAPT regimen,” said lead author Dr. Jesus Guzman.

The study also highlighted the challenges of managing DAPT in a population where patient follow-up and prescription adherence can be inconsistent. “We need to address the unique needs of these patients and focus on providing them with the necessary support and resources to manage their health effectively,” emphasized Dr. Jeff Taclob, a hepatology fellow at The University of Tennessee Health Science Center.

The study’s findings suggest that the PRECISE-DAPT score could help improve patient safety and outcomes by enabling more targeted management of bleeding risks in high-risk patients on DAPT.

Read More